vTv Therapeutics (VTVT) investor relations material

Executive summary

• Achieved $36.8 million in revenue for Q1 2026, driven by upfront and license payments from Newsoara and G42 agreements.

• Net income attributable to shareholders was $24.1 million, a significant turnaround from a $5.1 million loss in Q1 2025.

• Lead candidate cadisegliatin advanced in Phase 3 for type 1 diabetes, with enrollment for the CATT1 trial on track to complete in Q3 2026 and supportive studies planned.

• Expanded global rights for HPP737 to Newsoara, securing $20 million upfront and eligibility for up to $115 million in milestones and royalties.

• The company expects its cash position to fund operations through the anticipated CATT1 topline data readout.

Financial highlights

• Revenue increased to $36.8 million in Q1 2026 from $0 in Q1 2025, due to license and milestone payments.

• Research and development expenses rose to $9.0 million, up 217% year-over-year, reflecting increased clinical activity.

• General and administrative expenses increased to $4.6 million, up 25% year-over-year, mainly from higher payroll and share-based compensation.

• Cash and cash equivalents stood at $98.1 million as of March 31, 2026, up from $88.9 million at year-end 2025.

• Net income attributable to shareholders was $24.1 million ($1.94 basic, $1.65 diluted EPS), compared to a net loss of $5.1 million ($0.77 loss per share) in Q1 2025.

Outlook and guidance

• Expects continued losses and negative cash flow from operations as clinical trials progress.

• Plans to seek additional capital through equity, licensing, or strategic transactions.

• Enrollment for the CATT1 Phase 3 trial of cadisegliatin expected to complete in Q3 2026, with topline data readout anticipated thereafter.

• Additional supportive and registrational studies for cadisegliatin planned for 2026 and 2027.

• Current cash is expected to fund operations through the CATT1 topline data milestone.